Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | HRH1 | P35367 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11583277 | 0.88 | HTR2A (0.69) | HTR2AHRH1SLC6A4HTTMITF | |
| SCHEMBL13934317 | 0.85 | HTR2A (0.59) | HTR2AHRH1SLC6A4HTTMITF | |
| SCHEMBL3638413 | 0.80 | HTR2A (1.00) | HTR2AHRH1SLC6A4HTTLMNA | |
| SCHEMBL24302606 | 0.80 | MEN1 (0.55) | HTR2AHRH1SLC6A4TAAR1KMT2A | |
| SCHEMBL1977801 | 0.80 | ROCK2 (0.53) | HTR2AHRH1SLC6A4 | |
| SCHEMBL4883561 | 0.79 | HTR2A (0.67) | HTR2AHRH1SLC6A4HTTLMNA | |
| SCHEMBL6416831 | 0.78 | SLC6A4 (0.45) | HTR2AHRH1SLC6A4HTTMITF | |
| Hydrochloric Acid SCHEMBL5223012 | 0.78 | HTR2A (0.95) | HTR2AHRH1SLC6A4HTTLMNA | |
| SCHEMBL6900402 | 0.78 | HTR2A (0.70) | HTR2AHRH1SLC6A4LMNATAAR1 | |
| SCHEMBL11496175 | 0.77 | SLC6A4 (0.45) | HTR2AHRH1SLC6A4TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0028682-A2 | Intermediates useful at the preparation of compounds having anti-depressive or tranquilizing activity | Astra Läkemedel Aktiebolag (SE) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | HTR2A 2372/4885HRH1 900/4885SLC6A4 3455/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HTR2A 3482/4885HRH1 1319/4885SLC6A4 3867/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HTR2A 3482/4885HRH1 1319/4885SLC6A4 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.